Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Enrolling By InvitationNCT05210803
What this trial is testing

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie 116
Early research (Phase 1)Active Not RecruitingNCT06817343
What this trial is testing

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Neovascular (Wet) Age-related Macular Degeneration (AMD)
Exegenesis Bio 12
Post-approval studies (Phase 4)Study completedNCT02161575
What this trial is testing

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 103
Testing effectiveness (Phase 2)Looking for participantsNCT07776522
What this trial is testing

Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
West China Hospital 50
Large-scale testing (Phase 3)Active Not RecruitingNCT05407636
What this trial is testing

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Who this might be right for
AMDnAMDWet Age-related Macular Degeneration+3 more
AbbVie 735
Early research (Phase 1)Study completedNCT04635800
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Who this might be right for
Macular EdemaDiabetic Macular EdemaNeovascular Age-related Macular Degeneration+1 more
Novartis Pharmaceuticals 21
Large-scale testing (Phase 3)Looking for participantsNCT07482176
What this trial is testing

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc. 284
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178249
What this trial is testing

Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD

Who this might be right for
Wet Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd 60
Large-scale testing (Phase 3)Study completedNCT03823300
What this trial is testing

Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Who this might be right for
Wet Macular Degeneration
Hoffmann-La Roche 658
Early research (Phase 1)Study completedNCT06213038
What this trial is testing

A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration
Youxin Chen 12
Large-scale testing (Phase 3)Study completedNCT05989126
What this trial is testing

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Who this might be right for
Diabetic Macular Edema (DME)Neovascular Age-Related Macular Degeneration (nAMD)
Regeneron Pharmaceuticals 35
Early research (Phase 1)Study completedNCT05903794
What this trial is testing

EXG102-031 in Patients With wAMD (Everest)

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Exegenesis Bio 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07798375
What this trial is testing

Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age Related Macular Degeneration(nAMD)
Everest Medicines (China) Co.,Ltd. 244
Large-scale testing (Phase 3)Active Not RecruitingNCT06864988
What this trial is testing

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Who this might be right for
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics 480
Not applicableActive Not RecruitingNCT04645212
What this trial is testing

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Who this might be right for
Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc. 23
Large-scale testing (Phase 3)Study completedNCT04264819
What this trial is testing

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 295
Testing effectiveness (Phase 2)Study completedNCT03927690
What this trial is testing

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema
Novartis Pharmaceuticals 91
Large-scale testing (Phase 3)UnknownNCT05297292
What this trial is testing

Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Who this might be right for
Wet Age-related Macular Degeneration
Mabwell (Shanghai) Bioscience Co., Ltd. 433
Post-approval studies (Phase 4)Study completedNCT02581891
What this trial is testing

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Who this might be right for
Macular Degeneration
Bayer 287
Testing effectiveness (Phase 2)Active Not RecruitingNCT04514653
What this trial is testing

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie 146
Next Page